Jump Financial LLC Acquires Shares of 35,472 Myomo, Inc. (NYSEAMERICAN:MYO)

Jump Financial LLC acquired a new stake in Myomo, Inc. (NYSEAMERICAN:MYO) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 35,472 shares of the company’s stock, valued at approximately $228,000. Jump Financial LLC owned about 0.12% of Myomo at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. AIGH Capital Management LLC increased its holdings in shares of Myomo by 21.7% in the fourth quarter. AIGH Capital Management LLC now owns 3,381,567 shares of the company’s stock valued at $21,777,000 after purchasing an additional 602,719 shares during the last quarter. Portolan Capital Management LLC acquired a new position in shares of Myomo in the fourth quarter valued at about $2,446,000. Thompson Siegel & Walmsley LLC acquired a new position in shares of Myomo in the fourth quarter valued at about $1,288,000. Aristides Capital LLC acquired a new position in shares of Myomo in the fourth quarter valued at about $1,288,000. Finally, Renaissance Technologies LLC grew its stake in shares of Myomo by 39.5% in the fourth quarter. Renaissance Technologies LLC now owns 199,600 shares of the company’s stock valued at $1,285,000 after acquiring an additional 56,500 shares in the last quarter. 44.99% of the stock is currently owned by institutional investors and hedge funds.

Myomo Price Performance

MYO opened at $4.84 on Monday. Myomo, Inc. has a twelve month low of $2.76 and a twelve month high of $7.17. The business’s 50-day moving average price is $4.86. The company has a market capitalization of $146.41 million, a PE ratio of -21.04 and a beta of 1.68.

Insider Transactions at Myomo

In other Myomo news, insider Harry Kovelman sold 30,000 shares of the business’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $5.50, for a total transaction of $165,000.00. Following the sale, the insider now owns 97,973 shares of the company’s stock, valued at approximately $538,851.50. The trade was a 23.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Thomas F. Kirk bought 7,400 shares of the firm’s stock in a transaction on Thursday, March 13th. The shares were bought at an average cost of $5.00 per share, for a total transaction of $37,000.00. Following the purchase, the director now owns 255,933 shares of the company’s stock, valued at approximately $1,279,665. The trade was a 2.98 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 4.54% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on MYO shares. Craig Hallum upped their price target on shares of Myomo from $9.00 to $11.00 and gave the company a “buy” rating in a research note on Tuesday, March 11th. HC Wainwright upped their price target on shares of Myomo from $7.50 to $9.50 and gave the company a “buy” rating in a research note on Wednesday, March 12th. Alliance Global Partners restated a “buy” rating on shares of Myomo in a research note on Tuesday, March 11th. Finally, Ascendiant Capital Markets upped their price target on shares of Myomo from $9.00 to $11.00 and gave the company a “buy” rating in a research note on Monday, March 17th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, Myomo currently has an average rating of “Buy” and an average target price of $9.75.

Myomo Profile

Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient’s weak or paralyzed arm to enable and improve functional activities of daily living.